UNITUXIN (dinutuximab) injection, for intravenous use Initial U.S. Approval: 2015

UNITUXIN (dinutuximab) injection, for intravenous use Initial U.S. Approval: 2015

INDICATIONS AND USAGE
Unituxin is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
DOSAGE FORMS & STRENGTHS
Injection: 17.5 mg/5 mL (3.5 mg/mL) in a single-use vial.
Manufactured By: United Therapeutics Corp.
Prescribing Information URL: Click Here
Access to UNITUXIN ™ (dinutuximab) injection: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Dinutuximab (tradename Unituxin) and Dinutuximab beta (tradename Qarziba) are monoclonal antibodies used as a second-line treatment for children with high-risk neuroblastoma. Dinutuximab received marketing approval in the US and in the European Union in March 2015; the marketing approval was withdrawn in 2017. Dinutuximab beta received marketing approval in Europe in 2017.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.